[go: up one dir, main page]

EA200801274A1 - Лечение субъектов с хронической почечной недостаточностью ( хпн ) с применением соединений лантана - Google Patents

Лечение субъектов с хронической почечной недостаточностью ( хпн ) с применением соединений лантана

Info

Publication number
EA200801274A1
EA200801274A1 EA200801274A EA200801274A EA200801274A1 EA 200801274 A1 EA200801274 A1 EA 200801274A1 EA 200801274 A EA200801274 A EA 200801274A EA 200801274 A EA200801274 A EA 200801274A EA 200801274 A1 EA200801274 A1 EA 200801274A1
Authority
EA
Eurasian Patent Office
Prior art keywords
crf
treatment
lanthane
subjects
compounds
Prior art date
Application number
EA200801274A
Other languages
English (en)
Other versions
EA015171B1 (ru
Inventor
Рэймонд Дэнис Прат
Исобэл Вэбстер
Стэфэн Джп Дэммент
Original Assignee
Шир Интернэшнл Лайсенсинг Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37114439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200801274(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Шир Интернэшнл Лайсенсинг Б.В. filed Critical Шир Интернэшнл Лайсенсинг Б.В.
Publication of EA200801274A1 publication Critical patent/EA200801274A1/ru
Publication of EA015171B1 publication Critical patent/EA015171B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Лечение субъекта с симптомами хронической почечной недостаточности (ХПН), не страдающего, однако, почечной недостаточностью в терминальной стадии (ПНТС), может осуществляться путем перорального введения фармацевтического состава, содержащего в качестве активного ингредиента терапевтически эффективное количество нетоксичного соединения лантана. Введение соединения лантана может предотвращать прогрессирование ХПН, излечивать кальциноз мягких тканей и вторичный гиперпаратиреоз.
EA200801274A 2005-11-09 2006-11-07 Лечение субъектов с хроническим заболеванием почек с применением соединений лантана EA015171B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/272,563 US20070104799A1 (en) 2005-11-09 2005-11-09 Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
PCT/US2006/060598 WO2007056721A2 (en) 2005-11-09 2006-11-07 Treatment of chronic kidney disease (ckd) subjects using lanthanum compounds

Publications (2)

Publication Number Publication Date
EA200801274A1 true EA200801274A1 (ru) 2008-10-30
EA015171B1 EA015171B1 (ru) 2011-06-30

Family

ID=37114439

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801274A EA015171B1 (ru) 2005-11-09 2006-11-07 Лечение субъектов с хроническим заболеванием почек с применением соединений лантана

Country Status (25)

Country Link
US (1) US20070104799A1 (ru)
EP (1) EP1785142B1 (ru)
JP (1) JP2009514986A (ru)
KR (1) KR101318067B1 (ru)
CN (1) CN101304753B (ru)
AR (1) AR057876A1 (ru)
AT (1) ATE492284T1 (ru)
AU (1) AU2006311286B2 (ru)
BR (1) BRPI0619667A2 (ru)
CA (1) CA2629036C (ru)
CY (1) CY1111609T1 (ru)
DE (1) DE602006019043D1 (ru)
DK (1) DK1785142T3 (ru)
EA (1) EA015171B1 (ru)
ES (1) ES2362201T3 (ru)
IL (1) IL190860A0 (ru)
MY (1) MY147391A (ru)
NO (1) NO20082536L (ru)
NZ (1) NZ567519A (ru)
PL (1) PL1785142T3 (ru)
PT (1) PT1785142E (ru)
SI (1) SI1785142T1 (ru)
TW (1) TWI388329B (ru)
WO (1) WO2007056721A2 (ru)
ZA (1) ZA200804853B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0924533A2 (pt) * 2009-05-15 2015-06-30 Natco Pharma Ltd Processo para a preparação de carbonato de latânio di-hidratado
US20110033529A1 (en) * 2009-08-06 2011-02-10 Durga Prasad Samantaray Oral pharmaceutical paricalcitol formulations
EP2569418B1 (en) * 2010-05-12 2016-11-02 RegenMed (Cayman) Ltd. Bioactive renal cells
US8263119B2 (en) * 2010-12-01 2012-09-11 Shire Llc Capsule formulations containing lanthanum compounds
CN103120654A (zh) * 2012-02-23 2013-05-29 南京卡文迪许生物工程技术有限公司 醋酸镧或其水合物治疗血磷酸盐过多症的用途
CN103127041A (zh) * 2012-02-23 2013-06-05 南京卡文迪许生物工程技术有限公司 含有醋酸镧的药物组合物及其制备方法和用途
CN103127042A (zh) * 2013-03-07 2013-06-05 尹颖 一种稳定高效的降磷组合物
CN103127043A (zh) * 2013-03-07 2013-06-05 尹颖 一种稳定高效的降磷组合物
BR112021013046A2 (pt) * 2019-01-04 2021-09-21 Kaydence Pharma As Métodos para tratar doença renal crônica e doença cardiovascular, e, combinação sinérgica
CN111620363A (zh) * 2020-06-13 2020-09-04 南京卡文迪许生物工程技术有限公司 一种四水合碳酸镧的制备方法及其产品
CN111686008A (zh) * 2020-07-20 2020-09-22 温州海鹤药业有限公司 一种混煎中药去磷工艺

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE147261T1 (de) * 1992-01-13 1997-01-15 Pfizer Verfahren zur herstellung von tabletten mit hoher festigkeit
US5562921A (en) * 1994-07-15 1996-10-08 Sherman; Bernard C. Stable solid pharmaceutical compositions containing enalapril maleate
GB9506126D0 (en) * 1995-03-25 1995-05-10 Johnson Matthey Plc Pharmaceutical composition and method
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
US6160016A (en) * 1999-12-22 2000-12-12 Wisconsin Alumni Research Foundation Phosphorus binder
GB0015745D0 (en) * 2000-06-27 2000-08-16 Shire Holdings Ag Treatment of bone diseases
RU2296584C2 (ru) * 2001-04-23 2007-04-10 Шир Интернешнл Лайсенсин Б.В. Применение соединений редкоземельных металлов для предотвращения мочекаменной болезни
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
JP4896719B2 (ja) * 2003-08-26 2012-03-14 シャイアー ホールディングス アーゲー ランタン化合物を含む医薬製剤
US7381428B2 (en) * 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
KR20070054191A (ko) * 2004-07-27 2007-05-28 샤이어 파마세우티컬, 인크. 란탄 하이드록시 카보네이트를 이용한 고인산증 치료 방법
CA2583548A1 (en) * 2004-10-15 2006-04-27 Altairnano, Inc. Phosphate binder with reduced pill burden
US20060177415A1 (en) * 2004-11-01 2006-08-10 Burke Steven K Once a day formulation for phosphate binders
MX2007011153A (es) * 2005-03-17 2007-12-12 Amgen Inc Metodos para reducir la calcificacion.

Also Published As

Publication number Publication date
CA2629036A1 (en) 2007-05-18
ZA200804853B (en) 2014-01-29
EP1785142A1 (en) 2007-05-16
EP1785142B1 (en) 2010-12-22
AR057876A1 (es) 2007-12-26
BRPI0619667A2 (pt) 2011-10-11
IL190860A0 (en) 2008-11-03
HK1102545A1 (en) 2007-11-30
WO2007056721A2 (en) 2007-05-18
ATE492284T1 (de) 2011-01-15
US20070104799A1 (en) 2007-05-10
PT1785142E (pt) 2011-03-23
CN101304753B (zh) 2012-12-12
DK1785142T3 (da) 2011-03-14
AU2006311286B2 (en) 2012-08-23
SI1785142T1 (sl) 2011-07-29
TWI388329B (zh) 2013-03-11
CY1111609T1 (el) 2015-10-07
KR20080071175A (ko) 2008-08-01
ES2362201T3 (es) 2011-06-29
CN101304753A (zh) 2008-11-12
KR101318067B1 (ko) 2013-10-15
AU2006311286A1 (en) 2007-05-18
MY147391A (en) 2012-11-30
WO2007056721A3 (en) 2007-10-25
NZ567519A (en) 2011-04-29
DE602006019043D1 (de) 2011-02-03
NO20082536L (no) 2008-07-28
JP2009514986A (ja) 2009-04-09
PL1785142T3 (pl) 2011-07-29
TW200727905A (en) 2007-08-01
CA2629036C (en) 2014-07-22
EA015171B1 (ru) 2011-06-30

Similar Documents

Publication Publication Date Title
EA201070544A1 (ru) Новый класс терапевтических веществ, усиливающих диффузию низкомолекулярных соединений
EA200801274A1 (ru) Лечение субъектов с хронической почечной недостаточностью ( хпн ) с применением соединений лантана
DK1827386T3 (da) Orale sammensætninger til absorption af phosphor-forbindelser
RU2008139905A (ru) Фармацевтическая композиция для наружного применения
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
EA200801275A1 (ru) Стабилизированные составы карбоната лантана
EA200800172A1 (ru) 2,4-диаминопиримидины как ингибиторы aurora
EA201000105A1 (ru) Химические соединения
NO20091260L (no) Kombinasjonsbehandling for diabetes mellitus
EP4541418A3 (en) Assays for diagnosing and evaluating treatment options for fabry disease
MA29236B1 (fr) Prevention et traitement de troubles thromboemboliques
EA201100255A1 (ru) 5-алкинилпиримидины
MY151295A (en) Pyrimidyl indoline compound
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
WO2008022974A3 (fr) Composition antidiabetique contenant de l'acide chicorique et/ou l'un de ses metabolites
BRPI0507189A (pt) uso combinado de um agonista de glp-1 e compostos de gastrina
EA201100254A1 (ru) Новые соединения
EA200701845A1 (ru) Рофлумиласт для лечения сахарного диабета
BRPI0513603A (pt) uso de hidroxicarbonato de lantánio e composição farmacêutica
UA91848C2 (ru) Применение соединений диосметина в лечении и предотвращении тромботическим патологиям
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
CL2007001747A1 (es) Compuestos derivados de aril y heteroaril-etil-acilguanidina; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento y prevencion de la hipertension, insuficiencia cardiaca y afecciones renales entre otras.
HRP20100086T1 (hr) (2R,4aR,10bR)-6-(2,6-DIMETOKSIPIRIDIN-3-IL)-9-ETOKSI-8-METOKSI-1,2,3,4,4a,10b-HEKSAHIDROFENANTRIDIN-2-ol, HCI SOL
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
WO2007116297A3 (en) Use of aminapthone for the preparation of a medicament for treating arteriophaties

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM

PC4A Registration of transfer of a eurasian patent by assignment